Piecing it together: Does semaglutide fit the NAION puzzle?

Semaglutide, a glucagon-like peptide 1 (GLP-1) analogue, has gained considerable attention as a promising weight-loss drug, particularly among individuals with obesity or type 2 diabetes. This medication has been shown to help improve blood glucose control, promote satiety, and reduce the risk of cardiovascular events.¹ However, recent studies have suggested a possible link between semaglutide and an uncommon but serious eye condition known as nonarteritic anterior ischemic optic neuro­pathy (NAION).² This article will explore the potential mechanisms behind this association, its implications, and why more research is needed to determine causality.